Publication details

Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.

Authors

ŠIMARA Pavel STEJSKAL Stanislav KRONTORÁD KOUTNÁ Irena POTĚŠIL David TESAŘOVÁ Lenka POTĚŠILOVÁ Michaela ZDRÁHAL Zbyněk MAYER Jiří

Year of publication 2013
Type Article in Periodical
Magazine / Source American Journal of Hematology
MU Faculty or unit

Faculty of Informatics

Citation
Web PubMed
Doi http://dx.doi.org/10.1002/ajh.23419
Field Oncology and hematology
Keywords Chronic Myeloid Leukemia; Imatinib; Dasatinib
Attached files
Description Transient, potent BCR-ABL inhibition with tyrosine kinase inhibitors (TKIs) was recently demonstrated to be sufficient to commit chronic myeloid leukemia (CML) cells to apoptosis irreversibly. This mechanism explains the clinical efficacy of once-daily dasatinib treatment, despite the rapid clearance of the drug from the plasma. However, our in vitro data suggest that apoptosis induction after transient TKI treatment, observed in the BCR-ABL-positive cell lines K562, KYO-1, and LAMA-84 and progenitor cells from chronic phase CML patients, is instead caused by a residual kinase inhibition that persists in the cells as a consequence of intracellular drug retention. High intracellular concentrations of imatinib and dasatinib residues were measured in transiently treated cells. Furthermore, the apoptosis induced by residual imatinib or dasatinib from transient treatment could be rescued by washing out the intracellularly retained drugs. The residual kinase inhibition was also undetectable by the phospho-CRKL assay. These findings confirm that continuous target inhibition is required for the optimal efficacy of kinase inhibitors.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info